These findings indicate profound remodelling of the lymphoid and myeloid TME in response to PI3K/mTOR inhibition, which closely aligns with the results of a recent study that examined the effects of genetic and pharmacological inhibition of pik3ca and pik3cb in a genetically engineered mouse model of breast cancer with concurrent loss of Pten and Trp53. The gene discussed is PIK3CA; the disease is breast carcinoma.